Weight loss injections have emerged as a popular and effective option for individuals seeking long-term weight management. While lifestyle modifications like diet and exercise remain crucial, these medications offer an added advantage, leading to significant and sustainable results. This article explores the leading weight loss injection options, their mechanisms of action, efficacy, and other factors to consider.
Understanding Weight Loss Injections
Weight loss injections are prescription medications administered subcutaneously (under the skin) to aid in weight management. These injections, typically given in the abdomen, thigh, or upper arm, are designed to work as part of a medically supervised weight loss program. The most common type of weight loss injections are GLP-1 receptor agonists, initially developed for diabetes treatment.
How They Work
Medical weight loss medications mimic natural hormones that regulate hunger and blood sugar. These medications work by:
- Lowering appetite and cravings
- Slowing down gastric emptying (the rate at which food leaves the stomach)
- Improving insulin sensitivity
By mimicking natural hormones, these injections can offer more sustainable results than restrictive diets or over-the-counter supplements. Patients often experience weight loss and a reduced risk of conditions like type 2 diabetes, high blood pressure, and heart disease. However, it's essential to remember that these injections are most effective when combined with a reduced-calorie diet and increased physical activity.
Top Weight Loss Injection Options
Several injectable medications can lead to long-term weight loss. However, it's important to note that only Wegovy and Zepbound are explicitly approved by the FDA for this purpose. These medications are administered weekly via a subcutaneous injection using an injector pen, allowing patients or caregivers to administer the medication at home after proper instruction.
Read also: Principles of Diet Planning
1. Semaglutide (Ozempic and Wegovy)
Semaglutide is a GLP-1 receptor agonist available under the brand names Ozempic and Wegovy. While both contain semaglutide, they have different FDA approvals and dosages. Wegovy is approved for chronic weight management in adults and children aged 12 years and older with obesity or adults with overweight and at least one weight-related condition. Ozempic is approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
- Mechanism of Action: Semaglutide binds to GLP-1 receptors, stimulating insulin release from the pancreas when needed. It also slows down gastric emptying, promoting feelings of fullness and reducing food consumption.
- Dosage: Wegovy is available in single-dose pens with dosages of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. The starting dose is 0.25 mg subcutaneously once weekly for four weeks, gradually increasing to a maintenance dose of 1.7 mg or 2.4 mg (recommended). Ozempic injection pens deliver doses of 0.25 mg, 0.5 mg, 1 mg, and 2 mg. The initial dose is 0.25 mg given subcutaneously once weekly, increasing to 0.5 mg once weekly after four weeks. The maximum recommended dose of Ozempic for blood sugar control is 2 mg weekly.
- Efficacy: In clinical trials, Wegovy has demonstrated an average weight loss of around 15% of body weight over 68 weeks. In the STEP 1 trial, adults taking Wegovy lost an average of 15.9 kg (35 lb), or about 15% of their body weight, compared to placebo. Additionally, a significant percentage of participants experienced substantial weight loss: 84% lost 5% or more of their weight, 66% lost 10% or more, and 48% lost 15% or more.
- Cardiovascular Benefits: Ozempic and Wegovy are both approved for cardiovascular risk reduction, reducing the risk of cardiovascular death, heart attack, and stroke in specific populations.
- Treatment of MASH: Wegovy received accelerated approval in August 2025 for the treatment of adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.
2. Tirzepatide (Mounjaro and Zepbound)
Tirzepatide is a dual-acting GIP and GLP-1 receptor agonist available under the brand names Mounjaro and Zepbound. Mounjaro is approved for treating type 2 diabetes, while Zepbound is approved for chronic weight management in adults.
- Mechanism of Action: Tirzepatide activates both GIP and GLP-1 receptors, enhancing insulin secretion, suppressing glucagon secretion, decreasing food intake, and reducing body weight.
- Dosage: Mounjaro and Zepbound are available in single-use pens or vials with doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The recommended starting dosage is 2.5 mg subcutaneously once weekly, increasing to 5 mg once weekly after four weeks. If additional blood sugar control is needed, the dosage can be increased in 2.5 mg increments after at least four weeks on the current dose. The recommended maintenance dosages for Zepbound are 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly.
- Efficacy: In clinical trials, Zepbound has demonstrated significant weight loss results. In the SURMOUNT-1 study, participants using Zepbound lost an average of 21.8 kg (48 lb) or 21% of their body weight at the highest dose (15 mg), while those on the lowest dose (5 mg) lost an average of 15.5 kg (34 lb) or 15% of their body weight, compared to 3.2 kg (7 lb), or 3%, on placebo. The SURMOUNT-2 study showed that patients on Zepbound had a 47% greater relative weight loss compared to Wegovy, with an average weight reduction of 20.2% with Zepbound compared to 13.7% with Wegovy.
- Additional Benefits: Studies have also shown that Zepbound can lead to an average waist circumference reduction of 7.2 inches (18.4 cm), compared to 5.1 inches (13 cm) with Wegovy. In Phase 3 studies in patients with type 2 diabetes, those treated with Mounjaro lost an average of 5.5 kg (12 lb) to 11 kg (25 lb) over 52 weeks.
3. Liraglutide (Saxenda)
Liraglutide, marketed as Saxenda, is another GLP-1 receptor agonist approved for chronic weight management. It is administered as a daily injection.
- Dosage: Liraglutide is a daily injectable medication with doses starting at 0.6 mg to 3 mg a day.
- Efficacy: Some patients may lose 5-10% of body weight, especially with the higher dose of liraglutide.
Important Considerations
Side Effects
The most common side effects associated with these medications are gastrointestinal, including nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion (dyspepsia), and stomach (abdominal) pain. These side effects are typically mild to moderate and often occur during the dose escalation period. In rare cases, ileus (intestinal blockage) has been reported.
Contraindications
These medications carry a Boxed Warning for possible thyroid tumors, including cancer, observed in animal studies. They should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Read also: Alternatives to Fad Diets
Use Before Surgery
The American Society of Anesthesiologists suggests that adults and children on these types of GLP-1 medicines stop taking them prior to surgery due to the risk of delayed gastric emptying and potential aspiration during anesthesia.
BMI and Eligibility
Weight loss injections are typically indicated for adults with a BMI of 30 or higher or a BMI of 27 or higher with at least one weight-related health condition.
Other Weight Loss Medications
Besides injectable medications, several other options are available, including oral medications and medical devices.
Oral Medications
- Phentermine: An older medication, often used for short-term weight loss, but now sometimes included in long-term therapy.
- Phentermine-Topiramate (Qsymia): A combination medication that decreases appetite and cravings.
- Naltrexone-Bupropion (Contrave): Combines an opioid receptor antagonist with an antidepressant to decrease cravings and appetite.
- Orlistat (Xenical, Alli): A lipase inhibitor that reduces the amount of fat absorbed from food.
- Setmelanotide: A melanocortin-4 receptor agonist for chronic weight management in patients with obesity due to certain rare genetic disorders.
Medical Devices
- Plenity: A capsule that releases a super-absorbent hydrogel in the stomach, increasing satiety.
Future Trends
The landscape of weight loss medications is rapidly evolving, with pharmaceutical platforms predicting the launch of new GLP-1 medications annually. Companies like Lilly and Amgen are developing novel options, including oral GLP-1 inhibitors and triple-hormone receptor agonists.
Choosing the Best Injection
Selecting the best weight loss injection depends on individual factors such as health history, weight loss goals, insurance coverage, and tolerance to medication. Consulting with a healthcare provider is crucial to determine the most appropriate option.
Read also: Energy Consumption and Diets
Factors to Consider
- BMI and Health Conditions: Ensure your BMI aligns with medication guidelines, and consider any existing health conditions.
- Injection Schedule: Determine which injection schedule (weekly or daily) fits your lifestyle.
- Cost and Coverage: Check insurance coverage and out-of-pocket costs.
- Weight Loss Goals: Consider the desired amount and speed of weight loss.
Accessing Weight Loss Injections Safely
The safest way to access weight loss injections is through a medical weight loss clinic or a primary care provider who can prescribe FDA-approved versions and monitor your progress.
What to Expect During Your Appointment
- Review of health history and lab tests
- Personalized treatment plan
- Instruction on administering injections
- Scheduled follow-up visits
- Guidance on nutrition and exercise
The Importance of a Comprehensive Approach
Weight loss injections are most effective when combined with a healthy eating plan, regular physical activity, and a supportive network. These lifestyle changes are essential for long-term success and overall well-being.